Kymera Results Presentation Deck

Disease Severity Mild Moderate Severe Very Severe Extent of Disease AN Count Fistula Count Pain-NRS* Pruritus-NRS* EASI Score Baseline Disease Characteristics HS (n=13) (HS-PGA) Patients with any prior Therapy, n (%) Antibiotics/Antibacterials** Corticosteroids Adalimumab 10 1 2 Mean (min, max) 8 (5, 18) 4 (0, 15) 7 (3, 10) 5 (0, 10) 8 (62) 6 (46) 0 3 (23)² 1 (8)* AD (n=8) (VIGA-AD) 1 5 2 ! Mean (min, max) 8 (4, 10) 17.6 (4.4, 52.3) 7 (88) 1 (13) 7 (88) 0 0 Other Biologics includes 2 pts with very severe disease; *worst score over past week **includes clindamycin and chlorhexidine *1 patient with very severe disease received infliximab and bimekizumab (and adalimumab) AD=Atopic Dermatitis; AN=Abscess and Inflammatory Nodule Count; EASI-Eczema Area and Severity Index; HS-hidradenitis suppurativa; Min-minimum; Max=maximum; Pain-NRS-Skin Pain Numerical Rating Score; Pruritus-NRS-Peak Pruritus Numerical Rating Score; PGA-Physicians Global Assessment; IGA=Investigator Global Assessment KYMERA ©2022 KYMERA THERAPEUTICS, INC. PAGE 30

View entire presentation